Hematocrit Testing Market Size & Outlook, 2026-2034

Hematocrit Testing Market Overview

The global hematocrit testing market size is estimated at USD 2.05 billion in 2025 and is projected to reach USD 3.48 billion by 2034, growing at a CAGR of 6.12% during the forecast period. The remarkable market growth is attributed to the rising adoption of microfluidic hematocrit technologies, enabling rapid and decentralized blood testing.

Key Market Trends & Insights

• North America dominated the global market, accounting for a 39.05% share in 2025.
• The Asia Pacific region is projected to grow at the fastest pace, with a CAGR of 8.11% from 2026-2034.
• Based on product, the consumables & reagents segment held the highest market share of 39.67% in 2025.
• By application, the leukemia segment is projected to register the fastest CAGR growth of 7.88% during the forecast period.
• By end use, the hospitals segment dominated the market, accounting for 49.71% in 2025.
• The U.S. dominates the hematocrit testing market, valued at USD 682.87 million in 2024 and reaching USD 721.73 million in 2025.

Table: U.S. Hematocrit Testing Market Size (USD Million)

Source: Straits Research

Market Size & Forecast

• 2025 Market Size: USD 2.05 billion
• 2034 Projected Market Size: USD 3.48 billion
• CAGR (2026-2034): 6.12%
• Dominating Region: North America
• Fastest-Growing Region: Asia Pacific

The hematocrit testing market encompasses a wide range of diagnostic solutions used to measure the proportion of red blood cells in blood, supporting the detection and management of conditions such as anemia, leukemia, polycythemia vera, congenital heart diseases, and kidney disorders. The market includes handheld and benchtop hematocrit meters, analyzers, centrifuges, and essential consumables, which are utilized across hospitals, diagnostic laboratories, and other clinical settings to enable accurate and routine patient assessment.

Latest Market Trends

Integration of Smart Connectivity and Remote Diagnostics

A major emerging trend in the hematocrit testing market is the rapid adoption of smart connectivity features that enable remote diagnostics and seamless data integration. Modern hematocrit devices are increasingly equipped with Bluetooth, Wi-Fi, and cloud-based interfaces, allowing real-time transmission of test results to electronic health records and telemedicine platforms. This shift supports faster clinical decision-making, enhances patient monitoring in home care settings, and improves workflow efficiency across hospitals and diagnostic laboratories.

Expansion of Point-of-care Hematocrit Testing

A major trend in the hematocrit testing market is the increasing adoption of point-of-care (POC) testing devices. Portable hematocrit meters and handheld analyzers enable rapid bedside assessment of blood parameters, reducing dependency on centralized laboratories. This trend is driven by the growing demand for immediate diagnostic results in emergency care, home healthcare, and remote or resource-limited settings. As a result, patient management is becoming faster, more efficient, and more personalized.

To get more insights about this report Download Free Sample Report

Market Drivers

Growing Prevalence of Anemia and Blood Disorders

A major driver in the global hematocrit testing market is the rising prevalence of anemia and other blood-related disorders, which notably increases the need for accurate blood analysis. Conditions such as iron-deficiency anemia, sickle cell disease, and thalassemia require frequent hematocrit monitoring to guide treatment. For instance, the Centers for Disease Control and Prevention (CDC) estimates that nearly 1.62 billion people globally suffer from anemia, boosting demand for advanced hematocrit testing solutions.

Market Restraints

Stringent Regulatory Approval Process for Hematocrit Testing Devices

A major restraint in the hematocrit testing market is the stringent regulatory environment for diagnostic devices, which can delay product launches and increase compliance costs. For instance, in the U.S., hematocrit testing devices must obtain FDA clearance, a process that can take several months and require extensive clinical data. These regulatory hurdles slow market entry for innovative products and limit the adoption of advanced hematocrit testing solutions globally.

Market Opportunity

Expansion Into Emerging Markets With A High Anemia Burden

A key, relatively under‑highlighted opportunity for the hematocrit testing market lies in expanding penetration into emerging economies, particularly regions with a high anemia burden and limited diagnostic infrastructure. For example, many countries in South Asia and Africa face widespread nutritional deficiency, anemia and chronic blood disorders yet lack widespread lab facilities. As low-cost hematocrit devices and reagents become more accessible, demand is likely to surge in these underserved geographies, driving market growth.

Regional Analysis

North America dominated the hematocrit testing market in 2025, accounting for 39.05% market share, owing to its established healthcare infrastructure, including advanced hospitals, diagnostic centers, and research facilities. This enables widespread access to hematocrit testing, rapid adoption of innovative technologies, and efficient patient management, making the region a dominant contributor to global market growth.

In the U.S., a high prevalence of chronic diseases such as diabetes, cardiovascular disorders, and kidney disease, which require regular blood monitoring. This regional health burden increases demand for hematocrit testing across hospitals, clinics, and diagnostic laboratories, supporting sustained market growth across the U.S.

Asia Pacific Market Insights

Asia Pacific is emerging as the fastest-growing region with a CAGR of 8.11% from 2026-2034. The region benefits from the rapid expansion of private and chain diagnostic laboratories. Increasing investments in regional lab networks enhance testing accessibility, particularly in urban and semi-urban areas, boosting hematocrit test volumes and supporting the region’s fastest market growth.

China's hematocrit testing market is expanding rapidly, driven by the expansion of domestic manufacturing capacity for hematology analyzers and reagents. As local manufacturers scale up production under favorable policies, Chinese labs increasingly adopt cost-competitive, high-quality analyzers, reducing reliance on imported devices and accelerating market penetration nationwide.

Regional Market share (%) in 2025

Source: Straits Research

Europe Market Insights

Europe hematocrit testing market growth is driven by the rising demand for pre-operative screening and chronic disease monitoring in cardiovascular and oncology care. This demand for regular hematocrit assessments in pre-surgical protocols and long-term disease management increases test volumes across hospitals and diagnostic labs in Europe, thereby driving market growth.

A major driver of the German hematocrit testing market is its strong in vitro diagnostics (IVD) ecosystem, supported by harmonized regulatory compliance under the In Vitro Diagnostic Regulation (IVDR) and substantial public investment in diagnostic infrastructure, facilitating wider adoption of advanced hematocrit testing solutions.

Latin America Market Insights

Latin America hematocrit testing market growth is supported by the rapid expansion of both private and public diagnostic laboratory networks across urban and semi-urban areas. As these networks scale up, more facilities offer hematocrit testing, improving access and increasing overall test volumes throughout the region.

In Argentina, the hematocrit testing market is strengthened by the rising uptake of digital health and tele-diagnostic services in semi-urban and rural provinces. Government-supported telemedicine programs have expanded diagnostic reach beyond major cities, boosting demand for hematocrit testing as patients use remote consultations combined with local lab sampling, thereby strengthening market penetration across Argentina.

Middle East and Africa Market Insights

Middle East and Africa are witnessing steady market expansion, supported by the high prevalence of inherited hemoglobin disorders such as Sickle Cell Disease and Thalassemia, due to genetic predisposition and high rates of consanguineous marriages in several countries. This elevated disease burden necessitates frequent blood‑parameter monitoring, thereby increasing demand for hematocrit diagnostics.

In Saudi Arabia, the hematocrit testing market is driven by the surge in preventive health screening programs backed by increased health insurance coverage. As more citizens and expatriates obtain subsidized insurance, routine diagnostics, including hematocrit tests, become affordable and widespread, boosting overall test volumes nationwide.

Product Insights

The consumables & reagents segment dominated the market and accounted for a 39.67% revenue share in 2025. The segment benefits from the growing demand for customized, high-precision reagents tailored for specialized hematocrit assays. These reagents enhance test accuracy for specific patient populations, such as chronic disease patients, boosting adoption in clinical and research settings.

The analyzer & centrifuge segment is anticipated to witness the fastest growth, registering a CAGR of 7.24% during the forecast period. This growth is supported by the rising adoption of automated, high-throughput hematocrit analyzers that streamline sample processing, reduce manual errors, and deliver rapid results, catering to large hospitals and diagnostic centers seeking efficiency and improved laboratory workflow.

By Product Market Share (%), 2025

Source: Straits Research

Application Insights

The anemia segment accounted for the largest market share of 54.86% in 2025. This dominance is driven by expanded screening programs targeting iron deficiency anemia in vulnerable populations, particularly women and children. Early detection initiatives in schools and maternal health clinics have increased hematocrit testing demand, reinforcing the segment’s market dominance.

The leukemia segment is projected to register the fastest CAGR growth of 7.88% during 2026-2034, owing to the increasing use of hematocrit-based tests in minimal residual disease monitoring. These tests enable precise tracking of treatment response and early relapse detection, boosting demand in specialized oncology centers.

End Use Insights

The hospitals segment dominated the market in 2025 with a revenue share of 49.71%. This growth is attributed to the integration of hematocrit testing into emergency and critical care units. Rapid, on-site testing enables timely diagnosis and management of acute blood loss and anemia, enhancing patient outcomes and hospital efficiency.

The diagnostic labs segment is expected to witness the fastest CAGR growth during the forecast timeframe, as patients increasingly prefer standalone labs for convenient, quick, and affordable hematocrit testing. Easy access, shorter wait times, and widespread lab networks drive higher test volumes, fueling market expansion.

Competitive Landscape

The hematocrit testing market is moderately fragmented, with global diagnostics leaders and specialized device manufacturers competing across laboratory and point-of-care segments. Major players such as Danaher, Abbott, Siemens Healthineers, Sysmex, and Roche hold strong positions due to broad product portfolios and established clinical networks. Mid-tier companies, including EKF Diagnostics, HemoCue, Mindray, and Nova Biomedical, enhance competition through portable analyzers and affordable solutions.

Hilab: An Emerging Market Player

Hilab, a rapidly growing diagnostics innovator, is emerging as a notable player in the Hematocrit Testing market through its advanced point-of-care microfluidic and AI-driven testing solutions. The company’s compact hematology platforms enable near-patient hematocrit measurement with rapid turnaround times, making diagnostics more accessible in clinics, pharmacies, and remote settings. By combining portable hardware with cloud-based analytics, Hilab is enhancing testing efficiency and affordability, positioning itself as a next-generation player in decentralized hematocrit diagnostics.

List of key players in Hematocrit Testing Market

1. Abbott
2. Agappe Diagnostics
3. BD
4. bioMérieux SA
5. Bio‑Rad Laboratories, Inc.
6. Danaher
7. EKF Diagnostics Holdings plc
8. Hoffmann-La Roche Ltd.
9. Grifols S.A.
10. HemoCue AB
11. Heska Corporation
12. Hilab
13. HORIBA, Ltd.
14. Mindray Medical International Limited
15. Nihon Kohden Corporation
16. Nova Biomedical
17. Sensa Core
18. Siemens Healthineers
19. Sysmex Corporation
20. Thermo Fisher Scientific, Inc.
21. Others

To get more findings about this report Download Market Share

Strategic Initiatives

• February 2025:CytoChip received the FDA’s 510(K) clearance for its automated hematology analyzer Cito CBC System.